Market research
VEC.LSE Vectura Group plc
LSE GBP Healthcare
Latest close
As of 29 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 1B
- P/E ratio
- 8.2
- Analyst target
- 173.4
- Dividend yield
- 23.%
- Beta
- 0.45
Profile
Instrument facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- ISIN
- GB00BKM2MW97
- Market cap
- 1B
- P/E ratio
- 8.2
- Analyst target
- 173.4
- Dividend yield
- 23.%
- Beta
- 0.45
About
About Vectura Group plc
Vectura Group plc engages in the design, development, and supply of pharmaceutical products related to inhalation. Its products include flutiform, flutiform K-haler, Ultibro Breezhaler, Seebri Breezhaler, Enerzair Breezhaler, AirFluSal Forspiro, Airbufo Forspiro, Fluticasone Propionate and Salmeterol, Incruse Ellipta, Anoro Ellipta, Trelegy Ellipta, Relvar/Breo Ellipta, and Breelib. The company also provides formulation, process development and tech transfer, pharmaceutical analysis, product manufacturing, and device platforms services, as well as regulatory affairs, device vigilance, and pharmacovigilance services. In addition, it is developing VR315 (US), a generic Advair. Further, the company offers dry powder and pressurized metered dose inhalers, as well as vibrating mesh and jet nebulizers. Vectura Group plc was incorporated in 1997 and is based in Chippenham, the United Kingdom.
Research context
Vectura Group plc appears in PyInvesting’s London Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the VEC.LSE discussion.
5 years, 6 months ago
Vectura Group plc is currently in a long term uptrend where the price is trading 14.8% above its 200 day moving average.
From a valuation standpoint, the stock is 99.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.8.
Vectura Group plc's total revenue sank by 0.0% to $43M since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-4M since the same quarter in the previous year.
Finally, its free cash flow fell by 64.2% to $3M since the same quarter in the previous year.
Based on the above factors, Vectura Group plc gets an overall score of 2/5.